Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has
launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and
40 mg, a therapeutic equivalent generic version of NEXIUM®
(esomeprazole magnesium) Delayed-Release Capsules in the US market on
September 25, 2015, following the approval by the United States Food &
Drug Administration (USFDA).
The NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules
brand and generic had U.S. sales of approximately $5.2 Billion MAT for
the most recent twelve months ending in July 2015 according to IMS
Health*.
Dr. Reddy’s ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg
and 40 mg are available in bottle count size of 30.
NEXIUM® is a registered trademark of ASTRAZENECA AB
CORPORATION
*IMS National Sales Perspectives: Retail and Non-Retail
MAT July 2015
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is
an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three
businesses – Pharmaceutical Services & Active Ingredients, Global
Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services,
generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s
operates in markets across the globe. Our major markets include – USA,
Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words "may," "will," "should," "expects,"
"plans," "intends," "anticipates," "believes," "estimates," "predicts,"
"potential," or "continue" and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v)
the impact of acquisitions or reorganisation, including related
integration issues.
The company assumes no obligation to update any information contained
herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150927005122/en/
Copyright Business Wire 2015